Basis and therapeutical rationale of the urinary concentrating mechanism

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 155, 2007, Pages 2-7

  Rittig, S ^a   Frokiaer J ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; ANTIDIURETIC AGENT; AQUAPORIN; AQUAPORIN 2; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; CARBAMAZEPINE; DESMOPRESSIN; HYDROCHLOROTHIAZIDE; IMIPRAMINE; INDOMETACIN;

CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES INSIPIDUS; DOSE RESPONSE; DRUG FORMULATION; DRUG HALF LIFE; FLUID BALANCE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CONCENTRATING CAPACITY; MOLECULAR GENETICS; NOCTURIA; NOCTURNAL ENURESIS; PATHOGENESIS; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 34548166508     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01461.x     Document Type: Review

References (40)

1. Oliver G, Schafer EA. On the physiological action of extracts of pituitary body and certain other glandular organs: preliminary communication. J Physiol 1895 18 : 277 9.
2. Du Vigneaud V. Hormones of the posterior pituitary gland: oxytocin and vasopressin. Harvey Lect 1954 50 : 1 26.
3. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985 103 : 228 39.
4. Gottschalk CW, Mylle M. Micropuncture study of the mammalian urinary concentrating mechanism: evidence for the countercurrent hypothesis. Am J Physiol 1959 196 : 927 36.
5. Birnbaumer M, Hinrichs V, Themmen AP. Development and characterization of a mouse cell line expressing the human V2 vasopressin receptor gene. Mol Endocrinol 1990 4 : 245 54.
6. Preston GM, Agre P. Isolation of the cDNA for erythrocyte integral membrane protein of 28 kilodaltons: member of an ancient channel family. Proc Natl Acad Sci USA 1991 88 : 11110 4.
7. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993 361 : 549 52.
8. Nielsen S, Kwon TH, Christensen BM, Promeneur S, Frøkiaer K, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999 10 : 647 63.
9. Marples D, Knepper MA, Christensen EI, Nielsen S. Redistribution of aquaporin-2 water channels induced by vasopressin in rat kidney inner medullary collecting duct. Am J Physiol 1995 269 (Part 1 C655 64.
10. Edwards RM, Jackson BA, Dousa TP. ADH-sensitive cAMP system in papillary collecting duct: effect of osmolality and PGE2. Am J Physiol 1981 240 : F311 8.
11. Wall SM, Hans JS, Chou CL, Knepper MA. Kinetics of urea and water permeability activation by vasopressin in rat terminal IMCD. Am J Physiol 1992 262 (Part 2 F989 98.
12. Katsura T, Gustafson CE, Ausiello DA, Brown D. Protein kinase A phosphorylation is involved in regulated exocytosis of aquaporin-2 in transfected LLC-PK1 cells. Am J Physiol 1997 272 (Part 2 F817 22.
13. Christensen BM, Zelenina M, Aperia A, Nielsen S. Localization and regulation of PKA-phosphorylated AQP2 in response to V(2)-receptor agonist/antagonist treatment. Am J Physiol Renal Physiol 2000 278 : F29 42.
14. Bouley R, Breton S, Sun T et al. Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of aquaporin 2 in renal epithelial cells. J Clin Invest 2000 106 : 1115 26.
15. Pattaragarn A, Alon US. Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor. Pediatr Nephrol 2003 18 : 1073 6.
16. Christensen JH, Rittig S. Familial neurohypophyseal diabetes insipidus - an update. Semin Nephrol 2006 26 : 209 23.
17. Bichet DG. Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis 2006 13 : 96 104.
18. Robben JH, Sze M, Knoers NV, Deen PM. Rescue of vasopressin V2 receptor mutants by chemical chaperones: specificity and mechanism. Mol Biol Cell 2006 17 : 379 86.
19. Bernier V, Morello JP, Zarruk A et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 2006 17 : 232 43.
20. Yoshida M, Iwasaki Y, Asai M, Nigawara T, Oiso Y. Gene therapy for central diabetes insipidus: effective antidiuresis by muscle-targeted gene transfer. Endocrinology 2004 145 : 261 8.
21. Robertson GL. Dipsogenic diabetes insipidus: a newly recognized syndrome caused by a selective defect in the osmoregulation of thirst. Trans Assoc Am Physicians 1987 100 : 241 9.
22. Kirchlechner V, Koller DY, Seidl R, Waldhauser F. Treatment of nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride. Arch Dis Child 1999 80 : 548 52.
23. Knoers N, Monnens LA. Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus. J Pediatr 1990 117 : 499 502.
24. Robertson GL. Diabetes insipidus. Endocrinol Metab Clin North Am 1995 24 : 549 72.
25. Hjalmas K, Arnold T, Bower W et al. Nocturnal enuresis: an international evidence based management strategy. J Urol 2004 171 (Part 2 2545 61.
26. Rittig S, Knudsen UB, Norgaard JP, Pedersen EB, Djurhus JC. Abnormal diurnal rhythm of plasma vasopressin and urinary output in patients with enuresis. Am J Physiol 1989 256 (Part 2 F664 71.
27. Neveus T, von Gontard A, Hoebeke P et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol 2006 176 : 314 24.
28. Rittig S, Schaumburg H, Schmidt F et al. Long-term home studies of water balance in patients with nocturnal enuresis. Scand J Urol Nephrol 1997 183 (Suppl. 25 6.
29. Glazener CM, Evans JH. Desmopressin for nocturnal enuresis in children. Cochrane Database Syst Rev 2002 3 : CD002112.
30. Kamperis K, Rittig S, Jørgensen KA, Djurhuus JC. Nocturnal polyuria in monosymptomatic nocturnal enuresis refractory to desmopressin treatment. Am J Physiol Renal Physiol 2006 291 : F1232 40.
31. Hunsballe JM, Rittig S, Pedersen EB, Olesen OV, Djurhuus JC. Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. J Urol 1997 158 (Part 1 830 6.
32. Sener F, Hasanoglu E, Soylemezoglu O. Desmopressin versus indomethacin treatment in primary nocturnal enuresis and the role of prostaglandins. Urology 1998 52 : 878 81.
33. Yeung CK, Sihoe JD, Sit FK, Bower W, Sreedhar B, Lau J. Characteristics of primary nocturnal enuresis in adults: an epidemiological study. BJU Int 2004 93 : 341 5.
34. Bing MH, Moller LA, Jennum P, Mortensen S, Skovgaard LT, Lose G. Prevalence and bother of nocturia, and causes of sleep interruption in a Danish population of men and women aged 60-80 years. BJU Int 2006 98 : 599 604.
35. Matthiesen TB, Rittig S, Mortensen JT, Djurhuus JC. Nocturia and polyuria in men referred with lower urinary tract symptoms, assessed using a 7-day frequency-volume chart. BJU Int 1999 83 : 1017 22.
36. Robertson GL, Norgaard JP. Renal regulation of urine volume: potential implications for nocturia. BJU Int 2002 90 (Suppl. 3 7 10.
37. Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002 89 : 855 62.
38. van Kerrebroeck P, Rezapour M, Cortesse A, Thuroff J, Riis A, Nørgaard JP. Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study. Eur Urol 2007 52 : 221 9.
39. Rembratt A, Riis A, Norgaard JP. Desmopressin treatment in nocturia: an analysis of risk factors for hyponatremia. Neurourol Urodyn 2006 25 : 105 9.
40. Bosma R, Wynia K, Havlikova E, De Keyser K, Middel B. Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005 112 : 1 5.